Antengene Announces News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Antengene announces. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Antengene Announces Today - Breaking & Trending Today

TodayIR: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

(1)
DJ EQS-News: Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment EQS-News / 29/04/2021 / 11:36 UTC+8 Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment With the official release and implementation of the Overall Plan for the Construction of Hainan Free Trade Port, patient can now access global innovative medicines in mainland China. Recently, the global first-in-class selective inhibitor of nuclear export (SINE) compound, selinexor (XPOVIO(R)), was prescribed for the first time in mainland China at the Boao Super Hospital in Boao Lecheng Pilot Zone and has been authorized to be expanded beyond the Pilot Zone for the outpatient treatment of relapsed or refractory multiple myeloma (rrMM). Prescribing s ....

Hainan Province , Hong Kong , Boao Lecheng , Hongxia Yao , Asia Pacific , National Comprehensive Cancer Network Nccnr Guidelines , Hematological Lymphoma Department Of Hainan Cancer Hospital , Antengene Corporation Limited , People Daily , Karyopharm Therapeutics Inc , Boao Lecheng International Medical Tourism Pilot Zone , Financial Press , Patient Program , Name Patient Program , Hainan Chengmei Medicine Co Ltd , National Comprehensive Cancer Network , Antengene Announces , Selinexor Prescribed , First Time , Pilot Zone , Expanded Beyond , Outpatient Treatment , Outpatient Treatment With , Overall Plan , Hainan Free Trade Port , Boao Super Hospital ,

TodayIR: Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM

(2)
DJ EQS-News: Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM EQS-News / 28/01/2021 / 10:33 UTC+8 Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
Shanghai and Hong Kong, PRC, January 28, 2021 Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and /or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) accepted its New Drug Application (NDA) for ATG-010 (Selinexor, XPOVIO(R)), a first-in-class oral selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma ( rrMM). This is the fifth NDA for ATG-010 submitted by Antengene, after the four NDAs recently submitted in Australia, South Korea, Singapor ....

New Zealand , Hong Kong , South Korea , Kostenloser Wertpapierhandel , Jay Mei , Asia Pacific , Karyopharm Therapeutics Inc , Marketing Press , Drug Administration , Antengene Corporation Limited , European Medicines Agency , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Antengene Announces , Corporation Limited , New Drug Application , Karyopharm Therapeutics , Marketing Authorization Application , Medicines Agency , Safety Monitoring Board , Asia Pacific Region , Patients Beyond , Marketing Press Release , Dow Jones Newswires , புதியது ஜீலாந்து ,

TodayIR: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

(2)
DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
EQS-News / 21/12/2020 / 15:21 UTC+8
Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has
received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients
with Multiple Myeloma After At Least One Prior Therapy
Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple
Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R)
Addressable Patient Population -
Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated ....

United States , Hong Kong , Jay Mei , Asia Pacific , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , Drug Administration , Australian Therapeutic Goods Administration , Health Sciences Authority , Approval Program , European Medicines Agency , Antengene Corporation Limited , National Medical Products Administration , Connective Tissue Oncology Society , National Comprehensive Cancer Network , Antengene Announces , Combination Therapy , Addressable Patient Population , Only Approved Multiple Myeloma Drug Indicated , Once Weekly Bortezomib Combination Regimen , Multiple Myeloma Drug , New Mechanism , Action Approved , Second Line Setting Since , Comes Approximately Three Months Ahead , New Drug Application ,

TodayIR: Antengene Announces its U.S. Partner, -2-

TodayIR: Antengene Announces its U.S. Partner, -2-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Hong Kong , Kostenloser Wertpapierhandel , Jay Mei , Asia Pacific , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , Marketing Press , Drug Administration , Antengene Corporation Limited , Australian Therapeutic Goods Administration , Approval Program , Health Sciences Authority , European Medicines Agency , Connective Tissue Oncology Society , National Medical Products Administration , National Comprehensive Cancer Network , Antengene Announces , Combination Therapy , Addressable Patient Population , Only Approved Multiple Myeloma Drug Indicated , Once Weekly Bortezomib Combination Regimen , Multiple Myeloma Drug , New Mechanism , Action Approved , Second Line Setting Since ,